<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7211730\results\search\zoonosis\results.xml">
  <result pre="to imunodeficiency â€¢Immunodeficiency contributes to chronic diseases and the current" exact="Covid-19" post="pandemics. â€¢Environmental chemicals and microorganisms share similar molecular pathomechanisms"/>
  <result pre="respiratory syndrome coronavirus (SARS)-CoV in 2002â€&quot;2003 (Ksiazek et al., 2003)," exact="Middle East respiratory syndrome" post="(MERS)-CoV in 2012 (Zaki et al., 2012) and, in"/>
  <result pre="colitis, asthma, dengue virus disease (Jain et al., 2013), and" exact="swine flu" post="determined by pandemic H1N1 influenza virus (Bermejo-Martin et al.,"/>
  <result pre="and ARBs are unlikely to be harmful in patients with" exact="Covid-19" post="(Jarcho et al., 2020 1). Conversely, because of the"/>
  <result pre="and chemokines (Yang, 2020). The excessive immune reaction produced by" exact="SARS-CoV-2 infection" post="in the host can lead in some cases to"/>
  <result pre="drugs, such as ACE-inhibitors and angiotensin-receptor blockers (ARBs) to increase" exact="Covid-19" post="severity and case fatality rate (Day, 2020). This is"/>
  <result pre="i.e. both high and low ACE2 activity could theoretically increase" exact="Covid-19" post="severity (Guo et al., 2020). Therefore, more research is"/>
  <result pre="interaction between the ACE-inhibitor/ARB use and the susceptibility to increased" exact="Covid-19" post="severity. Observational studies are currently underway on this issue,"/>
  <result pre="of convincing clinical evidence of their benefits against severity of" exact="Covid-19" post="(Fang et al., 2020; ESC, 2020). It has been"/>
  <result pre="GS-441524. Its clinical significance was proved during the West African" exact="Ebola" post="virus epidemic of 2013â€&quot;2016 and the Kivu Ebola epidemic"/>
  <result pre="West African Ebola virus epidemic of 2013â€&quot;2016 and the Kivu" exact="Ebola" post="epidemic in 2018 (Warren et al., 2015). Given its"/>
  <result pre="Although Remdesivir has led to quick recoveries in symptoms of" exact="Covid-19" post="patients in a clinical trial, results from its Phase"/>
  <result pre="clinical trial, results from its Phase III trial involving severe" exact="Covid-19" post="patients are expected to be available soon. 6 Approaches"/>
  <result pre="be available soon. 6 Approaches and challenges to tackle the" exact="Covid-19" post="epidemics/pandemics It is well understood that COVID-19 outbreak and"/>
  <result pre="and 2) avoiding hospitals (and Intensive Care Units) overwhelmed by" exact="Covid-19" post="cases. The global spending on cancer therapies, cholesterol-lowering drugs,"/>
  <result pre="the non-observance of individual protection measures and treatment of mild" exact="Covid-19" post="cases in new temporary hospitals, the intensified competition and"/>
  <result pre="inhibitor that provides complete therapeutic protection against the development of" exact="Ebola" post="virus disease (EVD) in infected non-human primatesOpen Forum Infectious"/>
 </snippets>
</snippetsTree>
